167 related articles for article (PubMed ID: 28484093)
1. Enhanced antitumor efficacy of cisplatin for treating ovarian cancer in vitro and in vivo via transferrin binding.
Peng H; Jin H; Zhuo H; Huang H
Oncotarget; 2017 Jul; 8(28):45597-45611. PubMed ID: 28484093
[TBL] [Abstract][Full Text] [Related]
2. Lung cancer targeted therapy: Folate and transferrin dual targeted, glutathione responsive nanocarriers for the delivery of cisplatin.
Tan S; Wang G
Biomed Pharmacother; 2018 Jun; 102():55-63. PubMed ID: 29549729
[TBL] [Abstract][Full Text] [Related]
3. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
[TBL] [Abstract][Full Text] [Related]
4. Tumor targeting using polyamidoamine dendrimer-cisplatin nanoparticles functionalized with diglycolamic acid and herceptin.
Kesavan A; Ilaiyaraja P; Sofi Beaula W; Veena Kumari V; Sugin Lal J; Arunkumar C; Anjana G; Srinivas S; Ramesh A; Rayala SK; Ponraju D; Venkatraman G
Eur J Pharm Biopharm; 2015 Oct; 96():255-63. PubMed ID: 26277659
[TBL] [Abstract][Full Text] [Related]
5. Reversal of Cisplatin Resistance in Ovarian Cancer by the Multitargeted Nanodrug Delivery System Tf-Mn-MOF@Nira@CDDP.
Liu Y; Wang Y; Guan X; Wu Q; Zhang M; Cui P; Wang C; Chen X; Meng X; Ma T
ACS Appl Mater Interfaces; 2023 Jun; 15(22):26484-26495. PubMed ID: 37218712
[TBL] [Abstract][Full Text] [Related]
6. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
7. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound.
Yu T; Yang Y; Zhang J; He H; Ren X
Eur J Pharm Biopharm; 2015 Apr; 91():103-10. PubMed ID: 25668779
[TBL] [Abstract][Full Text] [Related]
8. Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer.
Bortot B; Mongiat M; Valencic E; Dal Monego S; Licastro D; Crosera M; Adami G; Rampazzo E; Ricci G; Romano F; Severini GM; Biffi S
Int J Nanomedicine; 2020; 15():4793-4810. PubMed ID: 32764921
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
[TBL] [Abstract][Full Text] [Related]
10. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA.
Shao Z; Shao J; Tan B; Guan S; Liu Z; Zhao Z; He F; Zhao J
Int J Nanomedicine; 2015; 10():1223-33. PubMed ID: 25709444
[TBL] [Abstract][Full Text] [Related]
11. A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles.
Li R; Zhang Q; Wang XY; Chen XG; He YX; Yang WY; Yang X
Drug Res (Stuttg); 2014 Oct; 64(10):541-7. PubMed ID: 24443309
[TBL] [Abstract][Full Text] [Related]
12. Targeted transferrin-modified polymeric micelles: enhanced efficacy in vitro and in vivo in ovarian carcinoma.
Sawant RR; Jhaveri AM; Koshkaryev A; Zhu L; Qureshi F; Torchilin VP
Mol Pharm; 2014 Feb; 11(2):375-81. PubMed ID: 24325630
[TBL] [Abstract][Full Text] [Related]
13. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Zhang X; Li J; Yan M
Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
[TBL] [Abstract][Full Text] [Related]
14. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor effects of follicle-stimulating hormone receptor-mediated hexokinase-2 depletion on ovarian cancer mediated by a shift in glucose metabolism.
Zhang M; Liu Q; Zhang M; Cao C; Liu X; Zhang M; Li G; Xu C; Zhang X
J Nanobiotechnology; 2020 Nov; 18(1):161. PubMed ID: 33160373
[TBL] [Abstract][Full Text] [Related]
16. Transferrin and tocopheryl-polyethylene glycol-succinate dual ligands decorated, cisplatin loaded nano-sized system for the treatment of lung cancer.
Xu G; Chen Y; Shan R; Wu X; Chen L
Biomed Pharmacother; 2018 Mar; 99():354-362. PubMed ID: 29358128
[TBL] [Abstract][Full Text] [Related]
17. Millepachine showed novel antitumor effects in cisplatin-resistant human ovarian cancer through inhibiting drug efflux function of ATP-binding cassette transporters.
Wu W; Liu Y; Ye H; Li Z
Phytother Res; 2018 Dec; 32(12):2428-2435. PubMed ID: 30123958
[TBL] [Abstract][Full Text] [Related]
18. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
[TBL] [Abstract][Full Text] [Related]
19. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo.
Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z
Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765
[TBL] [Abstract][Full Text] [Related]
20. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer.
Iinuma H; Maruyama K; Okinaga K; Sasaki K; Sekine T; Ishida O; Ogiwara N; Johkura K; Yonemura Y
Int J Cancer; 2002 May; 99(1):130-7. PubMed ID: 11948504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
